Alimta

 
National Institutes of Health

Related topics

Related topics

6 relations
LY 231514pemetrexed 500 MG Injection [Alimta]pemetrexed Injection [Alimta]

Broader (3)

pemetrexedpemetrexed disodiumpemetrexed disodium heptahydrate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer.
On August 19, 2004, pemetrexed for injection (Alimta); Eli Lilly and Company, Indianapolis, IN, http://www.lilly.com) received… (More)
Is this relevant?
Review
2005
Review
2005
The evolving role of pemetrexed (Alimta) in lung cancer.
Pemetrexed (Alimta; Eli Lilly and Co, Indianapolis, IN) is a multitargeted antifolate that inhibits several folate-dependent… (More)
Is this relevant?
Review
2004
Review
2004
Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
  • Araba A. Adjei
  • Clinical cancer research : an official journal of…
  • 2004
Pemetrexed (ALIMTA, LY231514, MTA) is a novel antimetabolite that inhibits at least three enzymes involved in the folate pathway… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression.
Pemetrexed (ALIMTA, MTA) is a novel thymidylate synthase (TS) inhibitor and has shown activity against colon cancer, mesothelioma… (More)
Is this relevant?
2003
2003
ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study.
BACKGROUND The purpose of this study was to evaluate ALIMTA (pemetrexed disodium, LY231514), a multi-targeted antifolate with… (More)
Is this relevant?
2002
2002
Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro.
PURPOSE Pemetrexed disodium (Alimta, multitargeted antifolate, LY231514; Eli Lilly and Co., Indianapolis, Indiana) ("pemetrexed… (More)
Is this relevant?
2002
2002
Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer.
BACKGROUND To evaluate the efficacy and safety of pemetrexed therapy for chemotherapy-naïve patients with surgically incurable… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.
The purpose of this study was to identify predictive factors for severe toxicity caused by antifolate-chemotherapy using… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2001
Review
2001
Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors.
Pemetrexed disodium (ALIMTA), "pemetrexed") is a novel, multi-targeted antifolate that has demonstrated promising clinical… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2000
2000
Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial.
BACKGROUND To evaluate the activity of MTA plus cisplatin in chemotherapy-naive patients with non-small cell lung cancer (NSCLC… (More)
Is this relevant?